nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.00241	0.00241	CcSEcCtD
Ceftazidime—Urticaria—Chlorambucil—ovarian cancer	0.00241	0.00241	CcSEcCtD
Ceftazidime—Abdominal pain—Chlorambucil—ovarian cancer	0.0024	0.0024	CcSEcCtD
Ceftazidime—Body temperature increased—Chlorambucil—ovarian cancer	0.0024	0.0024	CcSEcCtD
Ceftazidime—Renal failure—Paclitaxel—ovarian cancer	0.00239	0.00239	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00239	0.00239	CcSEcCtD
Ceftazidime—Colitis—Epirubicin—ovarian cancer	0.00239	0.00239	CcSEcCtD
Ceftazidime—Candida infection—Epirubicin—ovarian cancer	0.00238	0.00238	CcSEcCtD
Ceftazidime—Skin exfoliation—Epirubicin—ovarian cancer	0.00238	0.00238	CcSEcCtD
Ceftazidime—Inflammation—Doxorubicin—ovarian cancer	0.00237	0.00237	CcSEcCtD
Ceftazidime—Paraesthesia—Melphalan—ovarian cancer	0.00237	0.00237	CcSEcCtD
Ceftazidime—Vaginal infection—Epirubicin—ovarian cancer	0.00235	0.00235	CcSEcCtD
Ceftazidime—Aplastic anaemia—Epirubicin—ovarian cancer	0.00234	0.00234	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00233	0.00233	CcSEcCtD
Ceftazidime—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00231	0.00231	CcSEcCtD
Ceftazidime—Pain—Topotecan—ovarian cancer	0.00231	0.00231	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.0023	0.0023	CcSEcCtD
Ceftazidime—Vaginal inflammation—Doxorubicin—ovarian cancer	0.0023	0.0023	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00228	0.00228	CcSEcCtD
Ceftazidime—Bronchospasm—Docetaxel—ovarian cancer	0.00228	0.00228	CcSEcCtD
Ceftazidime—Coma—Epirubicin—ovarian cancer	0.00227	0.00227	CcSEcCtD
Ceftazidime—Nervous system disorder—Vinorelbine—ovarian cancer	0.00226	0.00226	CcSEcCtD
Ceftazidime—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00226	0.00226	CcSEcCtD
Ceftazidime—Pain—Melphalan—ovarian cancer	0.00226	0.00226	CcSEcCtD
Ceftazidime—Skin disorder—Vinorelbine—ovarian cancer	0.00224	0.00224	CcSEcCtD
Ceftazidime—Hypersensitivity—Chlorambucil—ovarian cancer	0.00223	0.00223	CcSEcCtD
Ceftazidime—Colitis—Doxorubicin—ovarian cancer	0.00221	0.00221	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Topotecan—ovarian cancer	0.00221	0.00221	CcSEcCtD
Ceftazidime—Candida infection—Doxorubicin—ovarian cancer	0.0022	0.0022	CcSEcCtD
Ceftazidime—Skin exfoliation—Doxorubicin—ovarian cancer	0.0022	0.0022	CcSEcCtD
Ceftazidime—Pancytopenia—Docetaxel—ovarian cancer	0.0022	0.0022	CcSEcCtD
Ceftazidime—Haemoglobin—Paclitaxel—ovarian cancer	0.0022	0.0022	CcSEcCtD
Ceftazidime—Haemorrhage—Paclitaxel—ovarian cancer	0.00219	0.00219	CcSEcCtD
Ceftazidime—Vaginal infection—Doxorubicin—ovarian cancer	0.00217	0.00217	CcSEcCtD
Ceftazidime—Neutropenia—Docetaxel—ovarian cancer	0.00216	0.00216	CcSEcCtD
Ceftazidime—Aplastic anaemia—Doxorubicin—ovarian cancer	0.00216	0.00216	CcSEcCtD
Ceftazidime—Hypotension—Vinorelbine—ovarian cancer	0.00216	0.00216	CcSEcCtD
Ceftazidime—Pruritus—Chlorambucil—ovarian cancer	0.00214	0.00214	CcSEcCtD
Ceftazidime—Urticaria—Topotecan—ovarian cancer	0.00214	0.00214	CcSEcCtD
Ceftazidime—Body temperature increased—Topotecan—ovarian cancer	0.00213	0.00213	CcSEcCtD
Ceftazidime—Abdominal pain—Topotecan—ovarian cancer	0.00213	0.00213	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—ovarian cancer	0.0021	0.0021	CcSEcCtD
Ceftazidime—Urticaria—Melphalan—ovarian cancer	0.0021	0.0021	CcSEcCtD
Ceftazidime—Phlebitis—Epirubicin—ovarian cancer	0.0021	0.0021	CcSEcCtD
Ceftazidime—Thrombophlebitis—Epirubicin—ovarian cancer	0.00209	0.00209	CcSEcCtD
Ceftazidime—Diarrhoea—Chlorambucil—ovarian cancer	0.00207	0.00207	CcSEcCtD
Ceftazidime—Paraesthesia—Vinorelbine—ovarian cancer	0.00207	0.00207	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Epirubicin—ovarian cancer	0.00207	0.00207	CcSEcCtD
Ceftazidime—Erythema multiforme—Paclitaxel—ovarian cancer	0.00207	0.00207	CcSEcCtD
Ceftazidime—Infestation NOS—Docetaxel—ovarian cancer	0.00206	0.00206	CcSEcCtD
Ceftazidime—Infestation—Docetaxel—ovarian cancer	0.00206	0.00206	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.00205	0.00205	CcSEcCtD
Ceftazidime—Renal failure—Docetaxel—ovarian cancer	0.00203	0.00203	CcSEcCtD
Ceftazidime—Flushing—Paclitaxel—ovarian cancer	0.00203	0.00203	CcSEcCtD
Ceftazidime—Jaundice—Docetaxel—ovarian cancer	0.00201	0.00201	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00199	0.00199	CcSEcCtD
Ceftazidime—Hypersensitivity—Topotecan—ovarian cancer	0.00199	0.00199	CcSEcCtD
Ceftazidime—Angiopathy—Paclitaxel—ovarian cancer	0.00198	0.00198	CcSEcCtD
Ceftazidime—Pain—Vinorelbine—ovarian cancer	0.00197	0.00197	CcSEcCtD
Ceftazidime—Immune system disorder—Paclitaxel—ovarian cancer	0.00197	0.00197	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00195	0.00195	CcSEcCtD
Ceftazidime—Hypersensitivity—Melphalan—ovarian cancer	0.00195	0.00195	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—ovarian cancer	0.00194	0.00194	CcSEcCtD
Ceftazidime—Hot flush—Epirubicin—ovarian cancer	0.00193	0.00193	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—ovarian cancer	0.00193	0.00193	CcSEcCtD
Ceftazidime—Vomiting—Chlorambucil—ovarian cancer	0.00193	0.00193	CcSEcCtD
Ceftazidime—Agranulocytosis—Docetaxel—ovarian cancer	0.00193	0.00193	CcSEcCtD
Ceftazidime—Menopausal symptoms—Epirubicin—ovarian cancer	0.00191	0.00191	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.00191	0.00191	CcSEcCtD
Ceftazidime—Pruritus—Topotecan—ovarian cancer	0.00191	0.00191	CcSEcCtD
Ceftazidime—Renal impairment—Epirubicin—ovarian cancer	0.0019	0.0019	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00189	0.00189	CcSEcCtD
Ceftazidime—Pruritus—Melphalan—ovarian cancer	0.00187	0.00187	CcSEcCtD
Ceftazidime—Dysgeusia—Paclitaxel—ovarian cancer	0.00186	0.00186	CcSEcCtD
Ceftazidime—Haemoglobin—Docetaxel—ovarian cancer	0.00186	0.00186	CcSEcCtD
Ceftazidime—Haemorrhage—Docetaxel—ovarian cancer	0.00185	0.00185	CcSEcCtD
Ceftazidime—Diarrhoea—Topotecan—ovarian cancer	0.00185	0.00185	CcSEcCtD
Ceftazidime—Lethargy—Epirubicin—ovarian cancer	0.00184	0.00184	CcSEcCtD
Ceftazidime—Urticaria—Vinorelbine—ovarian cancer	0.00183	0.00183	CcSEcCtD
Ceftazidime—Abdominal pain—Vinorelbine—ovarian cancer	0.00183	0.00183	CcSEcCtD
Ceftazidime—Body temperature increased—Vinorelbine—ovarian cancer	0.00183	0.00183	CcSEcCtD
Ceftazidime—Diarrhoea—Melphalan—ovarian cancer	0.00181	0.00181	CcSEcCtD
Ceftazidime—Nausea—Chlorambucil—ovarian cancer	0.0018	0.0018	CcSEcCtD
Ceftazidime—Vision blurred—Paclitaxel—ovarian cancer	0.00179	0.00179	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—ovarian cancer	0.00179	0.00179	CcSEcCtD
Ceftazidime—Dizziness—Topotecan—ovarian cancer	0.00178	0.00178	CcSEcCtD
Ceftazidime—Tremor—Paclitaxel—ovarian cancer	0.00178	0.00178	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—ovarian cancer	0.00177	0.00177	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—ovarian cancer	0.00176	0.00176	CcSEcCtD
Ceftazidime—Erythema multiforme—Docetaxel—ovarian cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Agitation—Paclitaxel—ovarian cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Angioedema—Paclitaxel—ovarian cancer	0.00174	0.00174	CcSEcCtD
Ceftazidime—Flushing—Docetaxel—ovarian cancer	0.00172	0.00172	CcSEcCtD
Ceftazidime—Vomiting—Topotecan—ovarian cancer	0.00172	0.00172	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—ovarian cancer	0.00171	0.00171	CcSEcCtD
Ceftazidime—Leukopenia—Paclitaxel—ovarian cancer	0.0017	0.0017	CcSEcCtD
Ceftazidime—Rash—Topotecan—ovarian cancer	0.0017	0.0017	CcSEcCtD
Ceftazidime—Hypersensitivity—Vinorelbine—ovarian cancer	0.0017	0.0017	CcSEcCtD
Ceftazidime—Dermatitis—Topotecan—ovarian cancer	0.0017	0.0017	CcSEcCtD
Ceftazidime—Headache—Topotecan—ovarian cancer	0.00169	0.00169	CcSEcCtD
Ceftazidime—Angiopathy—Docetaxel—ovarian cancer	0.00168	0.00168	CcSEcCtD
Ceftazidime—Vomiting—Melphalan—ovarian cancer	0.00168	0.00168	CcSEcCtD
Ceftazidime—Immune system disorder—Docetaxel—ovarian cancer	0.00167	0.00167	CcSEcCtD
Ceftazidime—Rash—Melphalan—ovarian cancer	0.00167	0.00167	CcSEcCtD
Ceftazidime—Dermatitis—Melphalan—ovarian cancer	0.00166	0.00166	CcSEcCtD
Ceftazidime—Convulsion—Paclitaxel—ovarian cancer	0.00165	0.00165	CcSEcCtD
Ceftazidime—Pruritus—Vinorelbine—ovarian cancer	0.00163	0.00163	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.00163	0.00163	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00161	0.00161	CcSEcCtD
Ceftazidime—Nausea—Topotecan—ovarian cancer	0.0016	0.0016	CcSEcCtD
Ceftazidime—Diarrhoea—Vinorelbine—ovarian cancer	0.00158	0.00158	CcSEcCtD
Ceftazidime—Dysgeusia—Docetaxel—ovarian cancer	0.00158	0.00158	CcSEcCtD
Ceftazidime—Nausea—Melphalan—ovarian cancer	0.00157	0.00157	CcSEcCtD
Ceftazidime—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00155	0.00155	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—ovarian cancer	0.00155	0.00155	CcSEcCtD
Ceftazidime—Dizziness—Vinorelbine—ovarian cancer	0.00153	0.00153	CcSEcCtD
Ceftazidime—Nervous system disorder—Paclitaxel—ovarian cancer	0.00152	0.00152	CcSEcCtD
Ceftazidime—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00152	0.00152	CcSEcCtD
Ceftazidime—Skin disorder—Paclitaxel—ovarian cancer	0.00151	0.00151	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.0015	0.0015	CcSEcCtD
Ceftazidime—Pancytopenia—Epirubicin—ovarian cancer	0.00148	0.00148	CcSEcCtD
Ceftazidime—Vomiting—Vinorelbine—ovarian cancer	0.00147	0.00147	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—ovarian cancer	0.00146	0.00146	CcSEcCtD
Ceftazidime—Rash—Vinorelbine—ovarian cancer	0.00146	0.00146	CcSEcCtD
Ceftazidime—Dermatitis—Vinorelbine—ovarian cancer	0.00145	0.00145	CcSEcCtD
Ceftazidime—Hypotension—Paclitaxel—ovarian cancer	0.00145	0.00145	CcSEcCtD
Ceftazidime—Headache—Vinorelbine—ovarian cancer	0.00145	0.00145	CcSEcCtD
Ceftazidime—Leukopenia—Docetaxel—ovarian cancer	0.00144	0.00144	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—ovarian cancer	0.00143	0.00143	CcSEcCtD
Ceftazidime—Convulsion—Docetaxel—ovarian cancer	0.0014	0.0014	CcSEcCtD
Ceftazidime—Paraesthesia—Paclitaxel—ovarian cancer	0.00139	0.00139	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—ovarian cancer	0.00139	0.00139	CcSEcCtD
Ceftazidime—Infestation—Epirubicin—ovarian cancer	0.00139	0.00139	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00138	0.00138	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—ovarian cancer	0.00137	0.00137	CcSEcCtD
Ceftazidime—Nausea—Vinorelbine—ovarian cancer	0.00137	0.00137	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—ovarian cancer	0.00137	0.00137	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00136	0.00136	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—ovarian cancer	0.00136	0.00136	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—ovarian cancer	0.00135	0.00135	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00134	0.00134	CcSEcCtD
Ceftazidime—Pain—Paclitaxel—ovarian cancer	0.00133	0.00133	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Epirubicin—ovarian cancer	0.00132	0.00132	CcSEcCtD
Ceftazidime—Anaphylactic shock—Docetaxel—ovarian cancer	0.00132	0.00132	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—ovarian cancer	0.0013	0.0013	CcSEcCtD
Ceftazidime—Nervous system disorder—Docetaxel—ovarian cancer	0.00129	0.00129	CcSEcCtD
Ceftazidime—Thrombocytopenia—Docetaxel—ovarian cancer	0.00129	0.00129	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—ovarian cancer	0.00129	0.00129	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—ovarian cancer	0.00129	0.00129	CcSEcCtD
Ceftazidime—Skin disorder—Docetaxel—ovarian cancer	0.00128	0.00128	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.00128	0.00128	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00127	0.00127	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—ovarian cancer	0.00127	0.00127	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—ovarian cancer	0.00126	0.00126	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—ovarian cancer	0.00126	0.00126	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—ovarian cancer	0.00125	0.00125	CcSEcCtD
Ceftazidime—Urticaria—Paclitaxel—ovarian cancer	0.00123	0.00123	CcSEcCtD
Ceftazidime—Hypotension—Docetaxel—ovarian cancer	0.00123	0.00123	CcSEcCtD
Ceftazidime—Abdominal pain—Paclitaxel—ovarian cancer	0.00123	0.00123	CcSEcCtD
Ceftazidime—Body temperature increased—Paclitaxel—ovarian cancer	0.00123	0.00123	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.00122	0.00122	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—ovarian cancer	0.0012	0.0012	CcSEcCtD
Ceftazidime—Paraesthesia—Docetaxel—ovarian cancer	0.00118	0.00118	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—ovarian cancer	0.00118	0.00118	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—ovarian cancer	0.00116	0.00116	CcSEcCtD
Ceftazidime—Flushing—Epirubicin—ovarian cancer	0.00116	0.00116	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—ovarian cancer	0.00116	0.00116	CcSEcCtD
Ceftazidime—Hypersensitivity—Paclitaxel—ovarian cancer	0.00114	0.00114	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00114	0.00114	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—ovarian cancer	0.00113	0.00113	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—ovarian cancer	0.00113	0.00113	CcSEcCtD
Ceftazidime—Pain—Docetaxel—ovarian cancer	0.00113	0.00113	CcSEcCtD
Ceftazidime—Pruritus—Paclitaxel—ovarian cancer	0.0011	0.0011	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—ovarian cancer	0.00109	0.00109	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00108	0.00108	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—ovarian cancer	0.00107	0.00107	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—ovarian cancer	0.00107	0.00107	CcSEcCtD
Ceftazidime—Diarrhoea—Paclitaxel—ovarian cancer	0.00106	0.00106	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—ovarian cancer	0.00105	0.00105	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—ovarian cancer	0.00104	0.00104	CcSEcCtD
Ceftazidime—Body temperature increased—Docetaxel—ovarian cancer	0.00104	0.00104	CcSEcCtD
Ceftazidime—Abdominal pain—Docetaxel—ovarian cancer	0.00104	0.00104	CcSEcCtD
Ceftazidime—Dizziness—Paclitaxel—ovarian cancer	0.00103	0.00103	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—ovarian cancer	0.00103	0.00103	CcSEcCtD
Ceftazidime—Agitation—Epirubicin—ovarian cancer	0.001	0.001	CcSEcCtD
Ceftazidime—Vomiting—Paclitaxel—ovarian cancer	0.000987	0.000987	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—ovarian cancer	0.000986	0.000986	CcSEcCtD
Ceftazidime—Rash—Paclitaxel—ovarian cancer	0.000979	0.000979	CcSEcCtD
Ceftazidime—Dermatitis—Paclitaxel—ovarian cancer	0.000978	0.000978	CcSEcCtD
Ceftazidime—Leukopenia—Epirubicin—ovarian cancer	0.000974	0.000974	CcSEcCtD
Ceftazidime—Headache—Paclitaxel—ovarian cancer	0.000973	0.000973	CcSEcCtD
Ceftazidime—Hypersensitivity—Docetaxel—ovarian cancer	0.00097	0.00097	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—ovarian cancer	0.000949	0.000949	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—ovarian cancer	0.000942	0.000942	CcSEcCtD
Ceftazidime—Pruritus—Docetaxel—ovarian cancer	0.000931	0.000931	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—ovarian cancer	0.000925	0.000925	CcSEcCtD
Ceftazidime—Nausea—Paclitaxel—ovarian cancer	0.000922	0.000922	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00092	0.00092	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—ovarian cancer	0.000901	0.000901	CcSEcCtD
Ceftazidime—Diarrhoea—Docetaxel—ovarian cancer	0.000901	0.000901	CcSEcCtD
Ceftazidime—Anaphylactic shock—Epirubicin—ovarian cancer	0.000888	0.000888	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—ovarian cancer	0.000872	0.000872	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—ovarian cancer	0.000871	0.000871	CcSEcCtD
Ceftazidime—Dizziness—Docetaxel—ovarian cancer	0.00087	0.00087	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—ovarian cancer	0.000869	0.000869	CcSEcCtD
Ceftazidime—Skin disorder—Epirubicin—ovarian cancer	0.000862	0.000862	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000851	0.000851	CcSEcCtD
Ceftazidime—Vomiting—Docetaxel—ovarian cancer	0.000837	0.000837	CcSEcCtD
Ceftazidime—Rash—Docetaxel—ovarian cancer	0.00083	0.00083	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—ovarian cancer	0.00083	0.00083	CcSEcCtD
Ceftazidime—Dermatitis—Docetaxel—ovarian cancer	0.000829	0.000829	CcSEcCtD
Ceftazidime—Headache—Docetaxel—ovarian cancer	0.000825	0.000825	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000821	0.000821	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—ovarian cancer	0.000806	0.000806	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000804	0.000804	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—ovarian cancer	0.000798	0.000798	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—ovarian cancer	0.000797	0.000797	CcSEcCtD
Ceftazidime—Nausea—Docetaxel—ovarian cancer	0.000782	0.000782	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—ovarian cancer	0.000768	0.000768	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000766	0.000766	CcSEcCtD
Ceftazidime—Pain—Epirubicin—ovarian cancer	0.000759	0.000759	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—ovarian cancer	0.000738	0.000738	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000726	0.000726	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000709	0.000709	CcSEcCtD
Ceftazidime—Urticaria—Epirubicin—ovarian cancer	0.000705	0.000705	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—ovarian cancer	0.000702	0.000702	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—ovarian cancer	0.000702	0.000702	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—ovarian cancer	0.000702	0.000702	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000672	0.000672	CcSEcCtD
Ceftazidime—Hypersensitivity—Epirubicin—ovarian cancer	0.000654	0.000654	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—ovarian cancer	0.000653	0.000653	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—ovarian cancer	0.000649	0.000649	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—ovarian cancer	0.000649	0.000649	CcSEcCtD
Ceftazidime—Pruritus—Epirubicin—ovarian cancer	0.000628	0.000628	CcSEcCtD
Ceftazidime—Diarrhoea—Epirubicin—ovarian cancer	0.000607	0.000607	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—ovarian cancer	0.000605	0.000605	CcSEcCtD
Ceftazidime—Dizziness—Epirubicin—ovarian cancer	0.000587	0.000587	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—ovarian cancer	0.000581	0.000581	CcSEcCtD
Ceftazidime—Vomiting—Epirubicin—ovarian cancer	0.000564	0.000564	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—ovarian cancer	0.000562	0.000562	CcSEcCtD
Ceftazidime—Rash—Epirubicin—ovarian cancer	0.00056	0.00056	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—ovarian cancer	0.000559	0.000559	CcSEcCtD
Ceftazidime—Headache—Epirubicin—ovarian cancer	0.000556	0.000556	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—ovarian cancer	0.000543	0.000543	CcSEcCtD
Ceftazidime—Nausea—Epirubicin—ovarian cancer	0.000527	0.000527	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—ovarian cancer	0.000522	0.000522	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—ovarian cancer	0.000518	0.000518	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—ovarian cancer	0.000517	0.000517	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—ovarian cancer	0.000515	0.000515	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—ovarian cancer	0.000488	0.000488	CcSEcCtD
